

RECEIVED  
CENTRAL FAX CENTER  
APR 03 2009

REMARKS

Revocation and New Power of Attorney & Change of Correspondence Address

Applicants include a Revocation of Power of Attorney with a New Power of Attorney and Change of Correspondence Address Form and a Statement under 37 C.F.R. §3.73(b) both signed by Lex M. Cowser, as President/CEO of the Assignee, CytoGenix, Inc. and appoints the undersigned to prosecute the above-referenced patent application before the U.S. Patent and Trademark Office.

Status of the Claims

Claims 66-69 and 71-88 are pending and claims 80, 82 and 84-88 are withdrawn. Claims 66-69, 71-79, 81 and 83 are subject to restriction. Claims 1-65 and 70 are canceled.

Election/Restrictions

Applicants hereby provisionally elect the sequence of SEQ ID NO: 8 as a species encompassed by SEQ ID NO: 7 for claim 78, with traverse. This species reads on claims 66, 76-79, 81, and 83.

The Examiner requires that the nucleotide sequences identified as N1 and N2 in SEQ ID NO: 7 in claim 78 should be specifically defined, including length of N<sub>1</sub> and N<sub>2</sub> and the specific nucleotides. Applicants have provisionally elected SEQ ID NO: 8 which is a specific oligonucleotide insert sequence (see claim 81) that contains the GGCTAGCTACAAACGA catalytic domain sequence of SEQ ID NO:

7 where N<sub>1</sub> is CCTGCTTA and N<sub>2</sub> is TGGTCACC (see PP 0056-0059 in U.S. Pub. No. 20070020635). Applicants respectfully request that the species defined by SEQ ID NO: 6 be rejoined with the provisionally elected SEQ ID NO: 8.

First, claim 78 depends from claim 77, which is drawn to a library comprising a plurality of vectors for expressing single-stranded oligodeoxynucleotides. Each vector has oligonucleotide inserts (as recited in claim 76 from which claim 77 depends) with sequences that differ one from the other. Claim 78 limits the oligonucleotide inserts to the different sequences defined by SEQ ID NO: 7 where N<sub>1</sub> and N<sub>2</sub> are independently random target binding domain sequences preferably, although not limited to, 8 nucleotides in length (PP 0057). Searching a single oligonucleotide insert sequence does not fall within the scope of claim 77 because the claim is drawn to a library of a plurality of vectors each with different insert sequences.

Second, claim 81 depends from claim 76 which limits the vectors (the same vectors comprising the library of claim 77) and recites specific insert sequences including SEQ ID NO: 6 and SEQ ID NO: 8. Thus, as no species election for claim 81 was required in either of the instant restriction requirement or the restriction requirement mailed June 27, 2008, Applicants respectfully submit that no undue burden is present for the Examiner to search both SEQ ID NO: 6 and SEQ ID NO: 8.

This is intended to be a complete response to the Restriction Requirement mailed February 5, 2009. If any issues remain outstanding, the Examiner is respectfully requested to telephone the undersigned attorney of record for

RECEIVED  
PAGE 04/08  
CENTRAL FAX CENTER

APR 03 2009

immediate resolution. Please charge the \$65 extension fee under 37 C.F.R. §1.17(a) to credit card identified on the enclosed Form PTO-2038. Only in the absence of Form PTO-2038, please debit any applicable fees from Deposit Acct. No. 07-1185 upon which the undersigned is allowed to draw.

Respectfully submitted,



Benjamin Aaron Adler, Ph.D., J.D.  
Registration No. 35,423  
Counsel for Applicant

Date: April 3, 2009  
ADLER & ASSOCIATES  
8011 Candle Lane  
Houston, Texas 77071  
Tel.: (713) 270-5391  
Fax: (713) 270-5361  
[Ben@adlerandassociates.com](mailto:Ben@adlerandassociates.com)